For patients with high-risk relapsed/refractory neuroblastoma driven by ALK, lorlatinib has been found to be both safe and effective.

Published Date: 05 Apr 2023

The Winship Cancer Institute of Emory University, the New Approaches to Neuroblastoma, and an international team of researchers have made a significant advancement in the treatment of neuroblastoma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot